Primary aldosteronism: Learning from the study of familial varieties

Journal of Hypertension

Volumn 18, Issue 9, 2000, Pages 1165-1176

  Stowasser, Michael ^a   Gordon, Richard D ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Familial hyperaldosteronism type II; Glucocorticoid remediable aldosteronism; Hypertension; Primary aldosteronism

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; ANGIOTENSIN 1 RECEPTOR; GLUCOCORTICOID; HYDROCORTISONE; STEROID 11BETA MONOOXYGENASE;

CLINICAL FEATURE; CUSHINGOID SYNDROME; DEXAMETHASONE SUPPRESSION TEST; EARLY DIAGNOSIS; FAMILIAL DISEASE; GENE EXPRESSION; GENE MUTATION; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENETIC SCREENING; HORMONAL REGULATION; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; POLYMERASE CHAIN REACTION; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RELIABILITY; REVIEW; SOUTHERN BLOTTING; TREATMENT OUTCOME;

EID: 0033817009     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200018090-00002     Document Type: Review

References (115)

1. Primary aldosteronism, a new clinical syndrome
2. Plasma renin activity in primary aldosteronism. Importance in differential diagnosis and in research of essential hypertension
3. Commentary on the incidence of primary aldosteronism. Current estimations based on objective data
4. Incidence of primary aldosteronism uncomplicated 'essential' hypertension
5. Prevalence of primary aldosteronism
6. Prevalence of primary and secondary hypertension: Studies in a random population
7. The incidence rate of phaeochromocytoma and Conns syndrome in Denmark, 1977-1981
8. The prevalence of hypertension in an unselected population, and the frequency of abnormalities of potassium, angiotensin II and aldosterone in hypertensive subjects
9. Patterns of adrenal secretion and urinary excretion of aldosterone and plasma renin activity in normal and hypertensive subjects
10. Hypokalemia in the hypertensive patient. With observations on the incidence of primary aldosteronism
11. Preoperative diagnosis of primary aldosteronism. Including a comparison of operative findings and preoperative tumour localization by adrenal phlebography
12. Primary aldosteronism with normal aldosterone levels in blood and urine
13. The diagnostic value of the 24 hour integrated concentration of plasma aldosterone
14. Plasma aldosterone-plasma renin activity ratio: A simple test to identify patients with primary aldosteronism
15. Primary aldosteronism
16. Primary aldosteronism and other forms of mineralocorticoid hypertension
17. Primary aldosteronism: Update on diagnosis and treatment
18. Potentially high prevalence of primary aldosteronism in a primary-care population
19. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity
20. Primary aldosteronism
21. High incidence of primary aldosteronism in 199 patients referred with hypertension
22. Evidence that primary aldosteronism may not be uncommon - Twelve percent incidence among antihypertensive drug trial volunteers
23. Primary aldosteronism: A missed diagnosis in 'essential hypertensives'?
24. A chimaeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension
25. Clinical and pathological diversity of primary aldosteronism including a new familial variety
26. Familial hyperaldosteronism type II - Five families with a new variety of primary aldosteronism
27. Autosomal dominant transmission and absence of HLA linkage in dexamethasone suppressible hyperaldosteronism
28. Genetic and pathophysiologic studies of a new kindred with glucocorticoid-suppressible hyperaldosteronism manifest in three generations
29. Glucocorticoid-remediable aldosteronism in a large kindred: Clinical spectrum and diagnosis using a characteristic biochemical phenotype
30. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism
31. Non-tumorous 'primary' aldosteronism: I. Type relieved by glucocorticoid (glucocorticoid-remediable aldosteronism)
32. Overproduction of sodium-retaining steroids by the zona glomerulosa is adrenocorticotropin-dependent and mediates hypertension in dexamethasone-suppressible aldosteronism
33. Hypertension corrected and aldosterone responsiveness to renin-angiotensin restored by long-term dexamethasone in glucocorticoid-suppressible hyperaldosteronism
34. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone
35. A new form of congenital adrenal hyperplasia
36. A case of glucocorticoid-responsive hyperaldosteronism
37. A kindred with familial glucocorticoid-suppressible aldosteronism
38. A new family with dexamethasone-suppressible hyperaldosteronism: Aldosterone unresponsiveness to angiotensin JJ
39. Dexamethasone-suppressible hyperaldosteronism: Studies on overproduction of 18-hydroxycortisol in three affected family members
40. Angiotensin-responsive aldosterone-producing adenoma masquerades as idiopathic hyperaldosteronism (IHA: Adrenal hyperplasia) or low-renin essential hypertension
41. Dexamethasone-suppressible hyperaldosteronism: Adrenal transitional cell hyperplasia?
42. Anomalous postural aldosterone response in glucocorticoid-suppressible hyperaldosteronism
43. Renin-aldosterone response to dexamethasone in glucocorticoid-suppressible hyperaldosteronism is altered by coexistent renal artery stenosis
44. Anomalous postural response of plasma aldosterone concentration in patients with aldosterone-producing adrenal adenoma
45. The plasma aldosterone response to angiotensin II infusion in aldosterone-producing adenoma and idiopathic hyperaldosteronism
46. Familial, dexamethasone-suppressible, normokalemic hyperaldosteronism
47. Evidence for an unidentified ACTH-induced steroid hormone causing hypertension
48. Effects of corticotropin on aldosterone excretion and plasma renin in normal subjects, in essential hypertension and in primary aldosteronism
49. Effects of glucocorticoid administration on aldosterone excretion and plasma renin in normal subjects, in essential hypertension and in primary aldosteronism
50. ACTH-dependent aldosterone excess due to adrenocortical adenoma: A variant of primary aldosteronism
51. Adrenocorticotrophin and steroid-induced hypertension in humans
52. Familial forms broaden horizons in primary aldosteronism
53. Transient fall and subsequent return of high aldosterone secretion by adrenal adenoma during continued dexamethesone administration
54. Effect of adrenocorticotropin on desoxycorticosterone, corticosterone and aldosterone excretion
55. The chimeric gene linked to glucocorticoid-suppressible hyperaldosteronism encodes a fused P-450 protein possessing aldosterone synthase activity
56. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2
57. Dexamethesone-suppressible hyperaldosteronism: Clinical, biochemical and genetic relations
58. Characterization of two genes encoding human steroid 11β-hydroxylase (P-450(11β))
59. Cloning and expression of a cDNA for human cytochrome P-450(aldo) as related to primary aldosteronism
60. Adrenal corticosteroid synthesis and hypertension
61. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase
62. Hypersecretion of a new corticosteroid, 18-hydroxycortisol in two types of adrenocortical hypertension
63. Biosynthesis of 18-oxocortisol by aldosterone-producing adrenal tissue
64. Elevated urinary excretion of 18-oxocortisol in glucocorticoid-suppressible aldosteronism
65. Distinguishing aldosterone-producing adenoma from other forms of hyperaldosteronism and lateralizing the tumour pre-operatively
66. Aldosterone-producing adenomas responsive to angiotensin pose problems in diagnosis
67. Clinical, biochemical and genetic approaches to the detection of familial hyperaldosteronism type I
68. Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: Aldosterone response to dexemethasone and long polymerase chain reaction for chimeric gene
69. Evaluation of the dexemethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism
70. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension
71. Rapid diagnosis and identification of cross-over sites in patients with glucocorticoid-remediable aldosteronism
72. A PCR-based method of screening individuals of all ages, from neonates to the elderly, for familial hyperaldosteronism type I
73. Rapid diagnosis of glucocorticoid suppressible hyperaldosteronism in infants and adolescents
74. Glucocorticoid-suppressible hyperaldosteronism: Effects of crossover site and parental origin of chimaeric gene on phenotypic expression
75. Variation of phenotype in patients with glucocorticoid-remediable aldosteronism
76. Glucocorticoid-remediable aldosteronism in a large kindred: Clinical spectrum and diagnosis using a characteristic biochemical phenotype
77. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism
78. Biochemical evidence of aldosterone overproduction and abnormal regulation in normotensive individuals with familial hyperaldosteronism type I
79. Severity of hypertension in familial hyperaldosteronism type I: Relationship to gender and to degree of biochemical disturbance
80. Glucocorticoid-remediable aldosteronism (GRA): Diagnosis, variability of phenotype and regulation of potassium homeostasis
81. In familial hyperaldosteronism type I, hybrid gene-induced aldosterone production dominates that induced by wild type genes
82. Evidence for persistent wild type aldosterone synthase gene dysfunction in glucocorticoid-treated familial hyperaldosteronism type I
83. Glucocorticoid-suppressible hyperaldosteronism and adrenal tumors occurring in a single French pedigree
84. Abnormality of aldosterone and cortisol late pathways in glucocorticoid-remediable aldosteronism
85. Altered 11β-hydroxylase activity in glucocorticoid-suppressible hyperaldosteronism
86. Dexamethasone-suppressible hypertension
87. Inherited forms of mineralocorticoid hypertension
88. Monogenic forms of mineralocorticoid hypertension: Insights into the pathogenesis of 'essential' hypertension?
89. Gluoccorticoid-remediable aldosteronism
90. Treatment of familial hyperaldosteronism type I: Only partial suppression of hybrid gene required to correct hypertension
91. Familial hyperaldosteronism, not suppressed by dexamethasone
92. Familial Conn's syndrome
93. Lineage of familial aldosterone-producing adenoma
94. Histological and biochemical distinctiveness of atypical aldosterone-producing adenomas responsive to upright posture and angiotensin
95. 320Ala convert the cortisol producing enzyme, CYP11B1, into an aldosterone producing enzyme
96. Mutations in CYP11B1 gene converting 11β-hydroxylase into an aldosterone-producing enzyme are not present in aldosterone-producing adenomas
97. PCR-SSCP analysis of the angiotensin II type 1 receptor gene in patients with aldosterone-producing adenomas
98. Somatic mutations of the angiotensin II (AT1) receptor gene are not present in aldosterone-producing adenoma
99. Linkage analysis of familial hyperaldosteronism type II - Absence of linkage of the gene encoding the angiotensin II receptor type 1
100. Familial hyperaldosteronism type II: Description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene
101. Disorders of steroid 11β-hydroxylase isoenzymes
102. Human CYP11B2 (aldosterone synthase) maps to human chromosome 8q24.3
103. Genetic analysis of aldosterone synthase in patients with idiopathic hyperaldosteronism
104. Genetics of primary aldosteronism
105. Primary aldosteronism - Some genetic, morphological and biochemical aspects of subtypes
106. The genetics of primary aldosteronism
107. A case of primary hyperparathyroidism, primary hyperaldosteronism, and Cushing's disease
108. The renin-angiotensin-aldosterone system in normotensive and hypertensive patients with acromegaly
109. Familial multiple endocrine adenomapeptic ulcer complex
110. Adrenal lesion in multiple endocrine neoplasia type 1
111. Allelic losses on chromosome 11q13 in aldosterone-producing adrenal tumors
112. Different allelic patterns at chromosome 11q13 in paired aldosterone-producing tumours and blood DNA
113. Aldosterone-secreting adenoma as part of multiple endocrine neoplasia (MENI): Loss of heterozygosity for polymorphic chromosome 11 deoxyribonucleic acid markers, including the MEN I locus
114. PCR-SSCP analysis of the p53 gene in tumours of the adrenal gland